The Claim
In patients hospitalized for myocardial infarction and discharged on high-intensity statins, early initiation of ezetimibe (within 12 weeks) is associated with a lower risk of major adverse cardiovascular events (MACE) over a 3-year period compared to delayed initiation (13 weeks to 16 months) or no initiation, with a hazard ratio of 1.29 (95% CI: 1.12–1.55) for no ezetimibe versus early use.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
If someone has a heart attack and starts taking a cholesterol drug called ezetimibe within 3 months, they’re less likely to have another heart problem in the next 3 years compared to those who wait longer or never start it.
See the scientific wording
In patients hospitalized for myocardial infarction and discharged on high-intensity statins, initiating ezetimibe within 12 weeks is associated with a lower risk of major adverse cardiovascular events (MACE) over 3 years compared to initiating it later (13 weeks to 16 months) or not at all, with a 3-year hazard ratio of 1.29 (95% CI: 1.12–1.55) for no ezetimibe versus early use.
What the research says
1 studyThe study found that patients who started ezetimibe soon after a heart attack had fewer heart problems over 3 years compared to those who started later or never started, which is exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.